Disc Medicine, Inc. (IRON) Stock Forecast
IRON analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.92 / 5 from 13 analysts
- Price target
- $103.17 average of analyst targets
- Upside to target
- +81.5% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.65
- 52-week range
- $55.74 – $94.11
IRON analyst ratings
13 analystsNumber of analysts at each rating.
IRON price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IRON earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.71 | −$1.93 | −$1.47 | −$1.77 | +3.3% | 9 |
| Current fiscal year (2026) | −$6.56 | −$7.24 | −$5.40 | −$6.01 | −9.2% | 9 |
| Next fiscal year (2027) | −$7.08 | −$8.42 | −$5.86 | −$6.56 | −7.9% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IRON revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 10 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 11 |
| Next fiscal year (2027) | $34.9M | $5.1M | $81.0M | 0.0% | 12 |
IRON EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IRON revenue: reported and forecast
IRON EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.86 | −$1.86 | −$1.74 | −$1.74 | −$1.71 | −7.8% | 1 up · 1 down |
| Current fiscal year (2026) | −$7.16 | −$7.16 | −$6.67 | −$6.67 | −$6.56 | −8.4% | 2 up · 0 down |
| Next fiscal year (2027) | −$7.59 | −$7.59 | −$7.26 | −$7.26 | −$7.08 | −6.7% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IRON earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IRON beat in 8 of 12.
What analysts expect from IRON
13 analysts cover Disc Medicine; their consensus rating is strong buy (4.92 on a 1–5 scale, where 5 is a strong buy). The average price target is $103.17, 81.5% above the latest close of $56.84. Analysts expect earnings of −$6.56 per share for 2026, −9.2% from a year earlier. For 2027 the average estimate is −$7.08 per share on revenue of $34.9 million. Disc Medicine beat the EPS estimate in 8 of the last 12 quarters.
Related: IRON income statement, IRON key metrics, IRON chart. See the IRON stock overview for the latest quote and news.
IRON forecast FAQ
What is Disc Medicine's price target?
The average analyst price target for Disc Medicine is $103.17, 81.5% above the latest close of $56.84.
Is Disc Medicine a buy, hold or sell?
Of 13 analysts covering Disc Medicine, 12 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Disc Medicine's EPS forecast?
Analysts forecast −$6.56 per share for 2026 (range −$7.24 to −$5.40); for 2027 the estimate is −$7.08.
When does Disc Medicine report earnings?
Disc Medicine is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-1.65.
Does Disc Medicine usually beat earnings estimates?
Disc Medicine reported EPS at or above the analyst estimate in 8 of the last 12 quarters.